Vividion Investor Wants IP Suit Over $2B Bayer Deal Revived
CHP III LP urged the Delaware Supreme Court on Wednesday to revive its suit over allegedly diverted intellectual property in Vividion Therapeutics Inc.'s $2 billion sale to Bayer Corp., while the...To view the full article, register now.
Already a subscriber? Click here to view full article